108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
在丙泊酚镇静下接受纤维支气管镜检查的患者中，用于抑制支气管镜反应所需的奥利西瑞啶 ED50 和 ED95 的估计：一项上下序贯分配试验
Authors Wu D, Liao Y, Qin Y, Wang Y, Xu B, Chen Q, Wang X, Wu X, Li Y , Guan X
Received 20 April 2025
Accepted for publication 10 September 2025
Published 30 September 2025 Volume 2025:19 Pages 8879—8889
DOI https://doi.org/10.2147/DDDT.S535435
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Tamer Ibrahim
Dongxue Wu,1,* Yeqing Liao,1,* Yanlin Qin,1,* Yafeng Wang,2 Bing Xu,3 Qiuling Chen,1 Xianting Wang,1 Xiaoshan Wu,1 Yalan Li,2 Xuehai Guan1
1Department of Anesthesiology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 2Department of Anesthesiology, the First Affiliated Hospital of Jinan University, Guangzhou, Guandong, People’s Republic of China; 3Department of Rehabilitation, the People`s Hospital of Guangxi Zhuang Autonomous, Nanning, Guangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xuehai Guan, Department of Anesthesiology, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi, 530021, People’s Republic of China, Tel +86-771-5356250, Email guan_xh@aliyun.com
Background: Bronchoscopy response is the main challenge during fiberoptic bronchoscopy (FOB) procedure. Opioids are commonly used to suppress bronchoscopy response. This study aimed to estimate the median effective dose (ED50) of oliceridine for suppressing bronchoscopy response during FOB under deep sedation with cipepofol.
Methods: This was an up-and-down sequential allocation trial. Patients were divided into male or female groups. The initial bolus of oliceridine was 40 μg/kg. The next dose of oliceridine was determined based on prior patient’s response to FOB with 10 μg/kg step size. After seven inflection points were completed, recruitment was terminated. Following a single bolus of oliceridine, all patients received cipepofol (initial bolus:0.4 mg/kg), with infusion rates subsequently titrated between 0.2 and 1.0 mg/kg/h to maintain bispectral index (BIS) values within the 40– 60 range. A laryngeal mask (LMA) was inserted when BIS ≤ 60. The endpoints were bronchoscopy response to FOB. Dixon’s up-and-down method was used to calculate the ED50 and ED95 of oliceridine required to alleviate the bronchoscopy response. A dose-response curve was generated using probit analysis.
Results: A total of 45 patients (23 males, 22 females) were enrolled in the study. The ED50 of oliceridine for suppressing the response to FOB under cipepofol sedation did not differ between males (median [interquartile range, IQR] 35.00 [35.00 to 36.00] μg/kg) and females (45.00 [35.00 to 45.00] μg/kg) (P=0.0723). Probit analysis showed the ED50 and ED95 of oliceridine required to suppress bronchoscopy response to FOB under deep sedation with cipepofol were 30.20 [95% confidence interval (CI):19.98 to 38.78] vs 40.47 [95% CI: 29.49 to 51.40] μg/kg and 46.49 [95% CI: 38.23 to 105.37] vs 57.55 [95% CI: 48.50 to 141.34] μg/kg in males and females respectively.
Conclusion: The ED50 and ED95 of oliceridine required to suppress bronchoscopy response under cipepofol sedation did not differ between males and females.
Trial Registration: Chictr.org.cn; identifier: ChiCTR2400086635.
Keywords: oliceridine, cipepofol, fiberoptic bronchoscopy, effective dose
1Department of Anesthesiology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 2Department of Anesthesiology, the First Affiliated Hospital of Jinan University, Guangzhou, Guandong, People’s Republic of China; 3Department of Rehabilitation, the People`s Hospital of Guangxi Zhuang Autonomous, Nanning, Guangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xuehai Guan, Department of Anesthesiology, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi, 530021, People’s Republic of China, Tel +86-771-5356250, Email guan_xh@aliyun.com
Background: Bronchoscopy response is the main challenge during fiberoptic bronchoscopy (FOB) procedure. Opioids are commonly used to suppress bronchoscopy response. This study aimed to estimate the median effective dose (ED50) of oliceridine for suppressing bronchoscopy response during FOB under deep sedation with cipepofol.
Methods: This was an up-and-down sequential allocation trial. Patients were divided into male or female groups. The initial bolus of oliceridine was 40 μg/kg. The next dose of oliceridine was determined based on prior patient’s response to FOB with 10 μg/kg step size. After seven inflection points were completed, recruitment was terminated. Following a single bolus of oliceridine, all patients received cipepofol (initial bolus:0.4 mg/kg), with infusion rates subsequently titrated between 0.2 and 1.0 mg/kg/h to maintain bispectral index (BIS) values within the 40– 60 range. A laryngeal mask (LMA) was inserted when BIS ≤ 60. The endpoints were bronchoscopy response to FOB. Dixon’s up-and-down method was used to calculate the ED50 and ED95 of oliceridine required to alleviate the bronchoscopy response. A dose-response curve was generated using probit analysis.
Results: A total of 45 patients (23 males, 22 females) were enrolled in the study. The ED50 of oliceridine for suppressing the response to FOB under cipepofol sedation did not differ between males (median [interquartile range, IQR] 35.00 [35.00 to 36.00] μg/kg) and females (45.00 [35.00 to 45.00] μg/kg) (P=0.0723). Probit analysis showed the ED50 and ED95 of oliceridine required to suppress bronchoscopy response to FOB under deep sedation with cipepofol were 30.20 [95% confidence interval (CI):19.98 to 38.78] vs 40.47 [95% CI: 29.49 to 51.40] μg/kg and 46.49 [95% CI: 38.23 to 105.37] vs 57.55 [95% CI: 48.50 to 141.34] μg/kg in males and females respectively.
Conclusion: The ED50 and ED95 of oliceridine required to suppress bronchoscopy response under cipepofol sedation did not differ between males and females.
Trial Registration: Chictr.org.cn; identifier: ChiCTR2400086635.
Keywords: oliceridine, cipepofol, fiberoptic bronchoscopy, effective dose